bizjournals.com — Rigel Pharmaceuticals Inc. will move an asthma drug into a Phase II trial. At the American Thoracic Society Conference in San Francisco, Rigel (NASDAQ: RIGL) said enrollment in the 276-patient trial will begin later this summer in patients with mild to moderate asthma. The trial would collect its final data in September 2013, according to ClinicalTrials.gov.